Deep Track Capital, LP - 05 Nov 2025 SCHEDULE 13G Report for MoonLake Immunotherapeutics Class A ordinary share, par value $0.0001 per share (MLTX)

Filing Manager
Deep Track Capital, LP
Reporting Manager
Deep Track Capital, LP
Security
MoonLake Immunotherapeutics Class A ordinary share, par value $0.0001 per share
Symbol
MLTX
Shares outstanding
71,363,328 shares
Disclosed Ownership
4,610,071 shares
Ownership
6.5%
Form type
SCHEDULE 13G
Filing time
12 Nov 2025, 16:02:05 UTC
Date of event
05 Nov 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Deep Track Capital, LP disclosed 6.5% ownership in MoonLake Immunotherapeutics Class A ordinary share, par value $0.0001 per share (MLTX) on 05 Nov 2025."

Quick Takeaways

  • Deep Track Capital, LP filed SCHEDULE 13G for MoonLake Immunotherapeutics Class A ordinary share, par value $0.0001 per share (MLTX).
  • Disclosed ownership: 6.5%.
  • Date of event: 05 Nov 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 12 Nov 2025, 16:02.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Deep Track Capital, LP 6.5% 4,610,071 0 4,610,071 /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser
Deep Track Biotechnology Master Fund, Ltd. 6.5% 4,610,071 0 4,610,071 /s/ David Kroin David Kroin, Director
David Kroin 6.5% 4,610,071 0 4,610,071 /s/ David Kroin David Kroin

Sponsored